SEB Asset Management AB Buys Shares of 68,814 Illumina, Inc. $ILMN

SEB Asset Management AB bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the first quarter, HoldingsChannel reports. The fund bought 68,814 shares of the life sciences company’s stock, valued at approximately $8,482,000.

Other institutional investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Illumina by 7.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock valued at $142,000 after acquiring an additional 79 shares during the last quarter. HighPoint Advisor Group LLC grew its position in Illumina by 3.7% during the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after acquiring an additional 80 shares during the last quarter. Toronto Dominion Bank increased its holdings in Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after purchasing an additional 92 shares in the last quarter. Panagora Asset Management Inc. increased its holdings in Illumina by 3.9% in the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after purchasing an additional 96 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in Illumina by 4.2% in the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after purchasing an additional 99 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Illumina news, CAO Scott D. Ericksen sold 1,500 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the completion of the sale, the chief accounting officer owned 14,946 shares of the company’s stock, valued at approximately $2,243,394.60. This represents a 9.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,003,769 shares of company stock valued at $155,710,908 over the last 90 days. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Up 4.3%

Shares of NASDAQ:ILMN opened at $192.53 on Wednesday. The firm has a market cap of $29.13 billion, a P/E ratio of 35.01, a P/E/G ratio of 2.73 and a beta of 1.47. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $196.66. The business has a fifty day simple moving average of $168.22 and a 200 day simple moving average of $144.20.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the business earned $0.97 EPS. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts predict that Illumina, Inc. will post 5.22 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Guggenheim lifted their price target on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, June 29th. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Barclays raised their price objective on shares of Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a report on Wednesday, June 24th. Leerink Partners lifted their target price on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday. Nine equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average target price of $156.88.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.